Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 433.45 million. The enterprise value is 350.35 million.
| Market Cap | 433.45M |
| Enterprise Value | 350.35M |
Important Dates
The next estimated earnings date is Thursday, March 12, 2026.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.40% |
| Owned by Institutions (%) | n/a |
| Float | 7.30M |
Valuation Ratios
The trailing PE ratio is 265.74.
| PE Ratio | 265.74 |
| Forward PE | n/a |
| PS Ratio | 1.19 |
| PB Ratio | 1.48 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | 15.21 |
| P/OCF Ratio | 9.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.80, with an EV/FCF ratio of 12.30.
| EV / Earnings | 213.89 |
| EV / Sales | 0.96 |
| EV / EBITDA | 12.80 |
| EV / EBIT | n/a |
| EV / FCF | 12.30 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.57.
| Current Ratio | 2.62 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 6.06 |
| Debt / FCF | 5.82 |
| Interest Coverage | -0.04 |
Financial Efficiency
Return on equity (ROE) is 0.49% and return on invested capital (ROIC) is -0.05%.
| Return on Equity (ROE) | 0.49% |
| Return on Assets (ROA) | -0.02% |
| Return on Invested Capital (ROIC) | -0.05% |
| Return on Capital Employed (ROCE) | -0.03% |
| Weighted Average Cost of Capital (WACC) | 4.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.69 |
| Inventory Turnover | 5.20 |
Taxes
In the past 12 months, Welgene Biotech has paid 638,000 in taxes.
| Income Tax | 638,000 |
| Effective Tax Rate | 30.57% |
Stock Price Statistics
The stock price has decreased by -19.48% in the last 52 weeks. The beta is 0.34, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -19.48% |
| 50-Day Moving Average | 18.84 |
| 200-Day Moving Average | 20.01 |
| Relative Strength Index (RSI) | 42.55 |
| Average Volume (20 Days) | 11,596 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 365.75 million and earned 1.64 million in profits. Earnings per share was 0.07.
| Revenue | 365.75M |
| Gross Profit | 152.85M |
| Operating Income | -143,000 |
| Pretax Income | 2.09M |
| Net Income | 1.64M |
| EBITDA | 14.04M |
| EBIT | -143,000 |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 253.71 million in cash and 165.97 million in debt, with a net cash position of 87.75 million or 3.77 per share.
| Cash & Cash Equivalents | 253.71M |
| Total Debt | 165.97M |
| Net Cash | 87.75M |
| Net Cash Per Share | 3.77 |
| Equity (Book Value) | 293.47M |
| Book Value Per Share | 12.39 |
| Working Capital | 215.54M |
Cash Flow
In the last 12 months, operating cash flow was 46.70 million and capital expenditures -18.21 million, giving a free cash flow of 28.49 million.
| Operating Cash Flow | 46.70M |
| Capital Expenditures | -18.21M |
| Free Cash Flow | 28.49M |
| FCF Per Share | 1.22 |
Margins
Gross margin is 41.79%, with operating and profit margins of -0.04% and 0.45%.
| Gross Margin | 41.79% |
| Operating Margin | -0.04% |
| Pretax Margin | 0.57% |
| Profit Margin | 0.45% |
| EBITDA Margin | 3.84% |
| EBIT Margin | -0.04% |
| FCF Margin | 7.79% |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 0.38% |
| FCF Yield | 6.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
Welgene Biotech has an Altman Z-Score of 2.37 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.37 |
| Piotroski F-Score | 5 |